McKee K T, Oro J G, Kuehne A I, Spisso J A, Mahlandt B G
United States Army Medical Research Institute of Infectious Diseases, Fort Detrick, Frederick, Md.
Intervirology. 1992;34(3):154-63. doi: 10.1159/000150276.
The protective efficacy of Candid No. 1, a live-attenuated vaccine against Argentine hemorrhagic fever (AHF), was evaluated in non-human primates. Twenty rhesus macaques immunized 3 months previously with graded doses of Candid No. 1 (16-127, 000 PFU), as well as 4 placebo-inoculated controls, were challenged with 4.41 log10 PFU of virulent P3790 strain Junin virus. All controls developed severe clinical disease; 3 of 4 died. In contrast, all vaccinated animals were fully protected; none developed any signs of AHF during a 105-day follow-up period. Viremia and virus shedding were readily detected in all placebo-vaccinated controls, while virus could be recovered only once (by amplification) from throat swabs of 2 Candid No. 1 vaccinees on day 21. Vigorous secondary-type neutralizing and immunofluorescent antibody responses were seen in most vaccinees that had received 3 log10 PFU Candid No. 1 or fewer; all others, including those receiving 127,200 PFU, maintained relatively stable titers during follow-up. Candid No. 1 was highly immunogenic and fully protective against lethal Junin virus challenge in rhesus macaques, even at extremely low (16 PFU) vaccine doses.
在非人灵长类动物中评估了抗阿根廷出血热（AHF）的减毒活疫苗Candid No. 1的保护效力。20只恒河猴在3个月前用不同剂量（16 - 127,000 PFU）的Candid No. 1进行免疫，另有4只接种安慰剂作为对照，随后用4.41 log10 PFU的强毒株朱宁病毒P3790株进行攻击。所有对照均出现严重临床疾病，4只中有3只死亡。相比之下，所有接种疫苗的动物均得到充分保护，在105天的随访期内均未出现任何AHF迹象。在所有接种安慰剂的对照中均易于检测到病毒血症和病毒排出，而在第21天仅从2只接种Candid No. 1疫苗的动物的咽拭子中通过扩增才检测到一次病毒。大多数接种3 log10 PFU或更少Candid No. 1的疫苗接种者出现强烈的二次型中和及免疫荧光抗体反应；所有其他接种者，包括接种127,200 PFU的接种者，在随访期间保持相对稳定的滴度。Candid No. 1具有高度免疫原性，即使在极低（16 PFU）疫苗剂量下，对恒河猴致死性朱宁病毒攻击也具有完全保护作用。
